• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

    1/8/25 3:17:00 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GNTA alert in real time by email

    Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector1

    SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025. The event will take place at INNOVIT (710 Sansome Street), San Francisco's Italian Innovation and Culture Hub, starting at 5:00 PM on Wednesday, January 15, 2025.

    Italian Trade Agency - Los Angeles Office

    Opening remarks at the event will be from the Ambassador of Italy to the U.S. H.E. Mariangela Zappia and Consul General of Italy in San Francisco Sergio Strozzi.

    The Italian life sciences ecosystem overview will be provided by Keynote Speaker Mauro Battocchi, the Director General for the Promotion of the Italy System at the Italian Ministry of Foreign Affairs and International Cooperation, who noted, "With a turnover of 270bn euros (equivalent to 11% of the country's GDP), Lifesciences are a powerhouse of the Italian economy. Thriving pharma, biotech and medical devices industries have attracted nearly 50 life science multinationals to set base in Italy for their productions and R&D activities. But there's ample room for growth! "Italy on the Move," organized by the Italian Foreign Ministry and the Italian Trade Agency (and hosted, in conjunction with the JP Morgan Healthcare Conference in San Francisco, at the Italian Innovation Center in Silicon Valley – INNOVIT) is the place to get to know more about the potentials the Italian life science ecosystems have to offer to international scientists, researchers, companies and investors."

    Ambassador Zappia said, "Italy's life sciences sector is large and fast growing, encompassing medical devices, pharmaceuticals, and healthcare services. Pharmaceuticals and medical devices represent the third most significant Italian export in the world, well before more iconic "Made in Italy" goods, such as apparels or wines. We cannot think of a better partner than the United States."

    Consul General Strozzi emphasized, "Italy on the Move is the event in San Francisco where US Healthcare Companies and Investors can meet Italian Companies to partner with or to invest in. It represents a unique occasion to know more about Italy ranking as 1st among the EU economies by pharma CDMO manufacturing value and 4th worldwide by patents productivity in Life Sciences[2]. I invite all American Life Sciences leaders and investors to join us at INNOVIT."

    "Since 2016, Italy on the Move has been the annual appointment with the Italian life sciences industry in the United States," said Erica Di Giovancarlo, ITA's Trade Commissioner in New York and Executive Director of the U.S. Network. "For this 8th edition, we are proud to present some of the best players in the Italian industry alongside relevant American counterparts, with the opportunity to get to know innovative SMEs and startups during a dedicated pitch event."

    The event will also include a panel discussion, "Navigating Transatlantic Partnerships in Life Sciences," moderated by Audrey Greenberg, Founder of the Center for Breakthrough Medicines and CEO and Founder of AG Capital Advisors.

    Panelists include leading life sciences executives:

    • Frederick Beddingfield - CEO, Rubedo Life Sciences
    • Fulvio Renoldi Bracco - CEO, Bracco Imaging
    • Elcin Barker Ergun - CEO and Member of the Board, Menarini Group
    • Karthic Jayaraman - Partner and Co-Head of Global Healthcare, TPG Capital
    • Pierluigi Paracchi - CEO, Co-Founder and Chairman, Genenta Science (NASDAQ:GNTA)
    • Maria Cristina Porta - General Director, ENEA Tech and Biomedical
    • Riccardo Zagaria - CEO, DOC Pharma

    In addition, five key Italian startups will provide pitch presentations, specifically Aavantgarde, Butterfly Decisions, Cellply, Medlea, and Sibylla Biotech.

    About the Italian Trade Agency 

    The Italian Trade Agency is the government agency which promotes the globalization of Italian firms under the aegis of the Ministry of Foreign Affairs. ITA helps to develop, facilitate and promote Italian economic and trade relations with foreign countries, focusing on the needs of SMEs, their associations and partnerships. ITA sustains Italian firms in their internationalization process, promoting the marketing of Italian goods and services as well as the image of "Made in Italy" products around the world, while facilitating outward Italian investments and encouraging FDI attraction into Italy. ITA's headquarters are based in Rome, and it works through a large network of offices around the world which are acknowledged as "Trade Promotion Offices" of the Embassies or Consulates of Italy. https://www.ice.it/en/

    LinkedIn: https://www.linkedin.com/company/italosangeles/

    Twitter: https://twitter.com/ITALosAngeles

    Facebook: https://www.facebook.com/italosangeles

    About INNOVIT

    The Italian Innovation and Culture Hub INNOVIT is a strategic initiative of the Italian Government for the promotion of the Country System's innovation in the United States. Its mission is to foster the Italian innovative companies, startups and tech ecosystems by connecting them with the Silicon Valley and US ones.

    Web: innovitsf.com

    LinkedIn: innovitsf

    Media Contact for Event Queries and Attendance

    Peter Collins

    [email protected]

    908-499-1200

    __________________________

    1 Assolombarda. (2024, July). La rilevanza della filiera Life Science in Lombardia https://www.assolombarda.it/centro-studi/la-rilevanza-della-filiera-life-science-in-lombardia-edizione-2024 Accessed 1 January 2024.

    2 https://www.investinitaly.gov.it/en/sectors/life-sciences

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/italian-trade-agency-to-host-italy-on-the-move-2025-side-event-during-jp-morgan-healthcare-conference-302346296.html

    SOURCE Italian Trade Agency

    Get the next $GNTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNTA

    DatePrice TargetRatingAnalyst
    6/29/2023$15.00Buy
    ROTH MKM
    7/25/2022$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $GNTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

      MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) based in Italy. This strategic partnership marks a major milestone, encompassing the successful production of critical starting materials, including the establishment of Cell Banks and the manufacturing of Plasmids for viral vector production. This collaboration represents a pivotal step in the advancement of immuno-oncology therapies, highlighting the powerful synergy between Genenta's innovative platform and Anemocyte's proven exper

      5/7/25 7:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

      MILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi, CEO Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at "Montalcini Global Biotech Tour" in Doha, Qatar on April 17th, 2025 at the Sheikh Fahad bin Jassim Al Thani theatre, Ministry of Commerce and Industry (MOCI) Building. Following the announcement of a €20 million ($22.7 million) strategic financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) — aimed at expanding Genenta's pipeline with the advancement of Temferon™ in metastatic Renal Cell Cancer (mRCC) — and the addition of approximately €3.0 million

      4/15/25 5:00:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

      MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) to support the expansion of its pipeline by advancing Temferon in metastatic Renal Cell Cancer (mRCC). ETB is a leading private foundation, supervised by the Italian Ministry of Enterprises and Made in Italy, managing over €1,7 billion in assets under management through two funds. With deep expertise in the biomedical sector, ETB is an established authority in identifying and supporting high-pote

      3/19/25 9:28:00 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNTA
    Leadership Updates

    Live Leadership Updates

    See more
    • ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

      Event showcases Italy as leading competitive hub for investments in biotech, healthcare, medical devices, and pharmaceuticals, and includes experts discussing private and public/institutional financial opportunities in the €270 Billion Italian life sciences sector1 SAN FRANCISCO, Jan. 8, 2025 /PRNewswire/ -- To promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International Cooperation will be hosting the eighth edition of "Italy on the Move," a side event of the 43rd annual J.P. Morgan Healthcare Conference 2025. The event will take place at INNOVIT (710 Sansome Street), San Francisco's Italian Innovation and Culture Hu

      1/8/25 3:17:00 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

      MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and

      5/6/24 6:25:00 AM ET
      $ARYD
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

      Corium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years' experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. ("BDSI"), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI,

      1/17/23 8:00:00 AM ET
      $AGRX
      $GNTA
      $NMTR
      $PG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Package Goods/Cosmetics

    $GNTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM resumed coverage on Genenta S.p.A. with a new price target

      ROTH MKM resumed coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $15.00

      6/29/23 9:11:48 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Genenta S.p.A. with a new price target

      H.C. Wainwright initiated coverage of Genenta S.p.A. with a rating of Buy and set a new price target of $25.00

      7/25/22 7:15:53 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

      SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

      2/12/24 4:05:34 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Genenta Science S.p.A. (Amendment)

      SC 13G/A - Genenta Science S.p.A. (0001838716) (Subject)

      2/10/23 6:02:50 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Genenta Science S.p.A.

      SC 13G - Genenta Science S.p.A. (0001838716) (Subject)

      2/25/22 1:17:49 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNTA
    SEC Filings

    See more
    • SEC Form 424B5 filed by Genenta Science S.p.A.

      424B5 - Genenta Science S.p.A. (0001838716) (Filer)

      3/28/25 4:30:29 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 20-F filed by Genenta Science S.p.A.

      20-F - Genenta Science S.p.A. (0001838716) (Filer)

      3/28/25 4:25:59 PM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Genenta Science S.p.A.

      6-K - Genenta Science S.p.A. (0001838716) (Filer)

      3/19/25 9:27:03 AM ET
      $GNTA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care